ESIC Drug Supply Tender Corrigendum 2026 - Tenders 170 to 175
The ESIC Drug Supply Tender Corrigendum 2026 has been issued by the ESI Corporation Headquarters, New Delhi to amend six parallel e-tender enquiries running together for the supply of drugs and medicines - Enquiry Nos. 170, 171, 172, 173, 174 and 175. The corrigendum is hosted on the ESIC tenders page under console reference 16269/2026, published on 11 May 2026 with a revised last date of 04 June 2026. Pharmaceutical manufacturers, marketing companies and authorised distributors who have downloaded any of the six parent e-tender enquiries must read this corrigendum carefully before submitting their bid on the CPP Portal.
Quick Glance
Enquiries Nos. 170 - 175 · Office ESIC HQ New Delhi · Published 11 May 2026 · Last date 4 June 2026 · Console 16269/2026
About the ESIC Drug Supply Corrigendum
ESIC HQ at Panchdeep Bhavan, New Delhi consolidates a large share of its annual pharmaceutical procurement through periodic e-tender enquiries for drugs and medicines for the ESIC dispensary and hospital network across India. Each enquiry is a numbered, standalone procurement covering a defined basket of formulations - generic medicines, biosimilars, life-saving drugs, oncology agents, anti-microbials, anaesthetics, etc.
This corrigendum is the formal mid-bid amendment to six such enquiries that are running in parallel - Enquiry Nos. 170, 171, 172, 173, 174 and 175. ESIC HQ uses corrigenda whenever a pre-bid query, internal review, vigilance feedback or external audit requires a change to dates, BoQ, scope clarifications, technical specifications, eligibility wording, sample submission process or the qualifying-criteria forms. Once issued, the corrigendum becomes part of the bid documents and overrides earlier conflicting text in the parent NIT.
Important Links
Download Corrigendum (ESIC Drug Supply Tenders 170 to 175 Corrigendum PDF): https://esic.gov.in/attachments/tenderfile/Corrigendum_in_r_o_e_Tender_Enquiries_Nos_170_171_172_173_174_175_for_supply_of_drugs_Medicines_1778513051.pdf
Online Bid Submission Portal (CPP Portal): https://eprocure.gov.in/eprocure/app
ESIC Tenders Page (Official): https://esic.gov.in/tenders
Scope of the Corrigendum
This corrigendum applies to the following six e-tender enquiries that are running in parallel at ESIC HQ for the supply of drugs and medicines - Enquiry Nos. 170, 171, 172, 173, 174 and 175. Each enquiry is a numbered procurement for a specific basket of medicines and is run separately on the CPP Portal with its own NIT number, Tender ID, BoQ and qualifying criteria.
By bundling these six enquiries under one corrigendum, ESIC HQ is communicating that the same set of amendments applies uniformly to all six tenders - typical reasons include:
Extension of the bid submission deadline (the listing currently shows a uniform new last date of 04 June 2026).
Revisions to the BoQ - addition or removal of items, change in pack size, change in dosage strength, change in formulation.
Amendments to the qualifying criteria - shelf-life requirement at the time of supply, WHO-GMP certification clauses, Schedule M compliance, manufacturing-licence wording, drug-licence validity period.
Clarifications on documentary evidence - CDSCO licence copies, product permission certificates, NSQ-product disclosures, analytical test reports.
Update to sample submission rules - quantity, packaging, dispatch address and timeline.
Update to evaluation rules - L1 selection methodology, splitting policy, rate-contract terms.
The corrigendum PDF itself is the authoritative source - download it from the ESIC tenders page and read each clause along with each of the six parent NITs and their annexures.
Who Should Act on the Corrigendum
This corrigendum is relevant to any pharmaceutical company who:
Has downloaded the parent NIT for any of e-Tender Enquiry Nos. 170, 171, 172, 173, 174 or 175 from the CPP Portal.
Is preparing a bid for the supply of drugs and medicines against any of these six tenders for ESIC's dispensary / hospital network.
Attended (or sent queries to) the pre-bid meetings of any of the six enquiries and is awaiting ESIC HQ's formal response.
If you have downloaded an earlier copy of the parent NIT or the BoQ Excel for any of these six enquiries, replace it with the latest version available on the CPP Portal after applying the corrigendum.
How to Bid After the Corrigendum
Log in to the Central Public Procurement Portal at https://eprocure.gov.in/eprocure/app with your registered Class III DSC.
Locate each of the six parent e-tender enquiries (Nos. 170 to 175) in your My Tenders folder; the corrigendum will be linked to each of them.
Download the corrigendum PDF (444.49 KB) from the ESIC tenders page or from the CPP Portal and read each amended clause carefully.
Cross-check the revised dates, BoQ, scope, qualifying criteria, sample requirements and evaluation rules against the version you had downloaded earlier.
Update your technical bid, financial bid, declarations, drug-licence proofs, WHO-GMP certificates and analytical test reports to reflect the corrigendum.
If you have already uploaded a bid against any of the six enquiries, withdraw the bid and re-upload the revised version before the revised cut-off announced in the corrigendum (currently 04 June 2026).
Print and retain the bid summary acknowledgement after re-upload as your audit trail; carry it as the entry pass for the bid opening meeting (date to be communicated by ESIC HQ for each enquiry).
Important Instructions
The corrigendum forms part of each of the six parent tender documents. Bidders are deemed to have read it whether or not they download it separately, so any non-compliance triggers rejection.
In case of conflict between any parent NIT and this corrigendum, the corrigendum prevails for that specific enquiry.
Any further changes will be uploaded only on https://eprocure.gov.in/eprocure/app and https://esic.gov.in/tenders - monitor both portals till the revised cut-off.
ESIC HQ reserves the right to issue further corrigenda, cancel or withdraw any individual enquiry without affecting the others, and without assigning reasons.
All amendments to dosage strength, pack size, manufacturer eligibility, shelf life or sample submission rules will be reflected directly in the corrigendum or in a subsequent corrigendum.
For specific clarifications on drug specifications, write to the ESIC HQ Drug Procurement Cell designated in each parent NIT.
Each enquiry has its own EMD / ePBG amount and bid-opening date - the corrigendum does not change the per-enquiry EMD amount unless explicitly stated; bidders should verify by reading the relevant section.
Bidders should ensure their valid drug licence (Form 20B / 21B or equivalent under the Drugs and Cosmetic Act 1940), Schedule M compliance, WHO-GMP certificate (where applicable) and any product-specific permission certificates are uploaded with the revised bid.
Common Mistakes to Avoid
Submitting on the original date: With the unified last date moved to 04 June 2026 on the ESIC tenders page, bidders should treat that as the binding deadline for each of the six enquiries unless an individual enquiry's CPP Portal listing displays a different date - check both.
Mixing the six enquiries: Each of the six enquiries is a separate procurement on the CPP Portal. The bid against one enquiry cannot be used for another - prepare and upload bids independently for each enquiry you wish to participate in.
Outdated BoQ: If the corrigendum revises the BoQ for any enquiry (item, strength, pack size), re-quote using the revised template. Submitting using the pre-corrigendum BoQ leads to a non-responsive bid.
Missing sample compliance: For drug tenders, sample submission rules are strict. Re-read the corrigendum's sample-submission clause and follow the prescribed timeline, packaging and dispatch address.
Skipping the analytical reports: ESIC HQ's drug tenders require batch-wise analytical test reports per the Drugs and Cosmetic Rules; uploading expired or non-conforming reports renders the bid non-responsive.
Ignoring CPP Portal notifications: The CPP Portal sends SMS / email alerts to bidders who have moved a tender to their My Tenders folder; ensure your mobile / email is active and that all six enquiries are in your folder.
Final Words
The ESIC Drug Supply Tender Corrigendum 2026 is a single, consolidated amendment to six parallel e-tender enquiries (Nos. 170 to 175) for the supply of drugs and medicines from ESIC HQ. Pharmaceutical companies bidding for any or all of these enquiries must download the corrigendum from the ESIC tenders page, apply its revisions to their bid, and re-upload on the CPP Portal before the revised cut-off of 04 June 2026. For more ESIC pharmaceutical tender updates and corrigenda, keep visiting SarkariWorld.org.